1. Activity of batracylin (NSC-320846) against solid tumors of mice

   • Patricia Mucci-LoRusso
   • Lisa Polin
   • Thomas H. Corbettv

   Preclinical Studies Pages: 295 - 306

2. Reduced variation in the clonogenic assay obtained by standardization of the cell culture conditions prior to drug testing on human small cell lung cancer cell lines

   • Peter Buhl Jensen
   • Henrik Roed
   • Heine Høi Hansen

   OriginalPaper Pages: 307 - 315

3. Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study

   • Eric K. Rowinsky
   • Louise B. Grochow
   • Ross C. Donehower

   Preclinical Studies Pages: 317 - 325

4. Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's Sarcoma (AIDS-KS)

   • A. Chachoua
   • M. Green
   • F. Muggia

   Clinical Studies Pages: 327 - 331

5. Phase II study of esorubicin (4′-deozydoxorubicin) in advanced epithelial carcinoma of the ovary: A Gynecologic Oncology Group study

   • William P. McGuire
   • John A. Blessing
   • Michael L. Berman

   Clinical Studies Pages: 333 - 336

6. A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent adenocarcinoma and adenosquamous carcinoma of the cervix

   • Robert E. Slayton
   • John A. Blessing
   • Harrison Ball

   Clinical Studies Pages: 337 - 340

7. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix

   • Gregory P. Sutton
   • John A. Blessing
   • Timothy DeEulis

   Clinical Studies Pages: 341 - 343

8. Announcement

   Announcement Pages: 345 - 345

9. Sixth NCI-EORTC symposium on new drugs in cancer therapy abstracts

   Abstract Pages: 347 - 487